ArticleThe Cochrane database of systematic reviews2025
Aspartate aminotransferase-to-platelet ratio index (APRI) for staging of fibrosis in adults with chronic hepatitis C.
Article in The Cochrane database of systematic reviews, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Noninvasive Assessment of Hepatic Steatosis in Living Liver Donors.Diagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis is a protocol for a Cochrane Review (diagnostic). The objectives are as follows: To determine the diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index (APRI) for staging and screening fibrosis in adults with chronic hepatitis C infection when compared with liver biopsy as the reference standard. To achieve this, we will compare at least significant fibrosis (stages F2-F4) to no significant fibrosis (stages F0-F1) as this group of people is prioritised for treatment; at least advanced fibrosis (stages F3-F4) compared to no advanced fibrosis (stages F0-F2) as this group of people is at high risk for developing complications, i.e. hepatocellular carcinoma; cirrhosis (stage F4) compared to no cirrhosis (stages F0-F3) as the duration and effectiveness of treatment in these population groups of people are different. Secondary objectives We also aim to identify the pooled sensitivity and specificity of the most common cut-off values of APRI for the staging of fibrosis in adults with chronic hepatitis C. We plan to investigate heterogeneity for the following covariates if adequate data are available (Investigations of heterogeneity). METHODOLOGICAL QUALITY: a) studies with high methodological quality; b) studies with low or unclear methodological quality Interval of liver biopsy and APRI: a) done in one day; b) more than one day, but less than or equal to three months Mean length of biopsy samples: a) less than 15 mm; b) mean length equal to or more than 15 mm Number of portal tracts in a biopsy sample: a) less than 11; b) number of portal tracts equal to or more than 11.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.